PepGen Inc

NASDAQ: PEPG
$4.41
+$0.09 (+2.1%)
Closing Price on November 22, 2024

PEPG Stock Chart and Intraday Price

PEPG Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 1 MARINA PARK DRIVE, SUITE 900, BOSTON, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 520.93M USD
Shares Outstanding 31,343,500
PepGen Inc. is a pioneering biotechnology firm based in Boston, Massachusetts, dedicated to advancing the treatment of severe neuromuscular and neurologic diseases. With a focus on oligonucleotide therapeutics, its flagship product, PGN-EDO51, is currently undergoing Phase I clinical trials aimed at combating Duchenne muscular dystrophy. Additionally, PepGen is exploring treatments for myotonic dystrophy type 1 and other forms of muscular dystrophy, demonstrating its commitment to addressing unmet medical needs in the neuromuscular field since its inception in 2018.

PEPG Articles

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Trey Thoelcke
Published: